<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A hallmark of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is aberrant DNA methylation, consisting of global hypomethylation and regional hypermethylation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes </plain></SENT>
<SENT sid="1" pm="."><plain>DNA methyltransferase inhibitors have been recognized as promising candidate anticancer drugs </plain></SENT>
<SENT sid="2" pm="."><plain>Drug development has focused on DNA methylation inhibitors with the goal of activating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes silenced by DNA methylation </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (5-AC; Vidaza), a global DNA methyltransferase inhibitor, was Food and Drug Administration approved to treat <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and is clinically tested for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this paper, it was demonstrated that 5'-aza-2'-deoxycytidine (5-azaCdR) activated both silenced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes and pro-metastatic genes by demethylation, raising the concern that it would promote <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>5-AzaCdR treatment increased the invasiveness of non-invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cell lines MCF-7 cells and ZR-75-1 and dramatically induced pro-metastatic genes; Urokinase plasminogen activator (uPA), matrix metalloproteinase 2 (MMP2), <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-associated gene (H-MTS1; S100A4) and C-X-C chemokine receptor 4 (CXCR4) </plain></SENT>
<SENT sid="6" pm="."><plain>The hypothesis that the blocking of cellular transformation activity of DNA methyltransferase inhibitor could be separated from the pro-metastatic activity was tested using short interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> (siRNA) targeted to the different DNA methyltransferase (DNMT) genes </plain></SENT>
<SENT sid="7" pm="."><plain>Although <z:mpath ids='MPATH_63'>depletion</z:mpath> of DNMT1 had the strongest effect on colony growth suppression in cellular transformation assays, it did not result in demethylation and activation of uPA, S100A4, MMP2 and CXCR4 in MCF-7 cells </plain></SENT>
<SENT sid="8" pm="."><plain><z:mpath ids='MPATH_63'>Depletion</z:mpath> of DNMT1 did not induce cellular invasion in MCF-7 and ZR-75-1 non-invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cell lines </plain></SENT>
<SENT sid="9" pm="."><plain>These data have implications on the design of new DNA methyltransferase inhibitor and on the proper utilization of current inhibitors </plain></SENT>
</text></document>